 Updated MCL and CLL data from the ongoing Phase 12 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reporting The ORR of 89 and CR rate of 43 for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to the historical ORR of 66 and CR rate of 20 ... The post Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022 appeared first on ForexTV... 